Underglycosylation of IgA in IgA nephropathy: More than a diagnostic marker?  by Roos, A. & van Kooten, C.
Kidney International (2007) 71       1089
commentar y
Scand 2004; 181: 463–469.
5. Loffing J, Kaissling B. Sodium and calcium 
transport pathways along the mammalian distal 
nephron: from rabbit to human. Am J Physiol 
Renal Physiol 2003; 284: F628–F643.
6. Meneton P, Loffing J, Warnock DG. Sodium 
and potassium handling by the aldosterone-
sensitive distal nephron: the pivotal role of the 
distal and connecting tubule. Am J Physiol Renal 
Physiol 2004; 287: F593–F601.
7. Kovacikova J, Winter C, Loffing-Cueni D et al. 
The connecting tubule is the main site of the 
furosemide-induced urinary acidification by 
the vacuolar H+-ATPase. Kidney Int 2006; 70: 
1706–1716.
8. Ren Y, Garvin JL, Liu R, Carretero OA. Crosstalk 
between the connecting tubule and the afferent 
arteriole regulates renal microcirculation. Kidney 
Int 2007; 71: 1116–1121. 
9. Barajas L, Powers K, Carretero O et al. 
Immunocytochemical localization of renin and 
kallikrein in the rat renal cortex. Kidney Int 1986; 
29: 965–970.
10. Dorup J, Morsing P, Rasch R. Tubule-tubule 
and tubule-arteriole contacts in rat kidney 
distal nephrons. A morphologic study based 
on computer-assisted three-dimensional 
reconstructions. Lab Invest 1992; 67: 761–769.
see original article on page 1148
Underglycosylation of IgA in 
IgA nephropathy: More than a 
diagnostic marker?
A Roos1,2 and C van Kooten2
Moldoveanu et al. present a diagnostic test for IgA nephropathy 
based on the presence of undergalactosylated IgA in serum. This 
underglycosylated IgA appears to be overrepresented in serum of 
IgA nephropathy patients and is most likely related to mesangial IgA 
deposition. Further studies on the nature, production, regulation, and 
cellular and molecular interactions of this undergalactosylated IgA 
may facilitate disease diagnosis and provide further insight into the 
pathogenesis of this important disease.
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IgA nephropathy is the most common 
primary glomerulonephritis worldwide. 
Classically it is defi ned by the presence 
of immune deposits dominated or codo-
minated by IgA, oft en in the presence of 
complement and other immunoglobulins. 
Although IgA nephropathy may show only 
slow deterioration of renal function, the 
disease progresses during several decades 
into end-stage renal disease in up to 30% 
of cases. Treatment of IgA nephropathy is 
a matter of debate, hampered by defi cits in 
knowledge about disease pathogenesis.1
IgA nephropathy may present with a 
range of clinical manifestations, including 
asymptomatic urinary abnormalities such 
as microscopic or macroscopic hematuria 
and/or proteinuria, but also a nephrotic 
syndrome or acute renal failure. Diagno-
sis of IgA nephropathy requires a renal 
biopsy, in which the presence of mesangial 
IgA in the absence of evidence for lupus 
nephritis is the hallmark of the disease.
Several lines of evidence indicate that 
IgA nephropathy is a systemic disease 
rather than a primary disease of the kid-
ney. Patients with IgA nephropathy who 
receive a renal transplant often show 
recurrence of IgA deposits in the graft . 
Furthermore, patients with IgA nephropa-
thy show abnormalities in circulating IgA, 
including an increased concentration and 
an abnormal glycosylation. Moldoveanu 
and colleagues2 (this issue) present a 
straightforward serologic assay for IgA 
nephropathy based on the assessment of 
abnormally glycosylated IgA. This test 
may serve as a diagnostic tool for patients 
with IgA nephropathy, thereby possibly 
bypassing the need for renal biopsy in at 
least some of the patients. Th ese fi ndings 
will be discussed below in the context of 
recent developments in the fi eld.
In IgA nephropathy, three diff erent IgA-
containing compartments are worthwhile 
to study in order to understand the dis-
ease pathogenesis: mucosal IgA, circulat-
ing IgA, and mesangial IgA.
IgA present in the mesangium of IgA 
nephropathy patients is believed to be 
polymeric in nature and largely consists 
of IgA1, although occasionally co-deposi-
tion of IgA2 has been reported. Although 
detailed biochemical studies on mesangial 
IgA are strongly hampered by the limited 
availability of precious biopsy mate-
rial, several studies have established that 
mesangial IgA shows undergalactosyla-
tion as compared with normal serum 
IgA.3,4 Furthermore, recent studies indi-
cate the presence of secretory IgA in the 
mesangium of at least a sub-population of 
IgA nephropathy patients.5
An important theme in studies on IgA 
nephropathy relates to the production site 
of mesangial IgA. Th e bulk of IgA is pro-
duced by mucosal B cells as dimeric IgA 
joined by J chain, which is subsequently 
covalently linked to secretory component 
upon its transepithelial transport. Secre-
tory IgA consists of IgA1 and IgA2 in 
variable proportions and plays an impor-
tant role in the maintenance of mucosal 
immunity. Circulating IgA is mainly 
produced by B cells in the bone marrow. 
In contrast to mucosal IgA, serum IgA 
consists of more than 90% IgA1 and is 
largely monomeric. However, part of cir-
culating IgA is in a polymeric form. Th is 
large-sized IgA contains a number of 
molecular variants, including dimeric IgA 
with J chain, secretory IgA, presumably 
leaked from the epithelial surfaces to the 
circulation, and alternatively polymerized 
monomeric IgA that may contain soluble 
receptor molecules, immune complexes, 
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and matrix molecules. Polymeric serum 
IgA contains more IgA2 than monomeric 
serum IgA.6 Th e presence of secretory 
IgA and the overrepresentation of IgA2 
in polymeric serum IgA may suggest that 
at least part of large-sized serum IgA is of 
mucosal origin.
Many studies have focused on circulat-
ing IgA in IgA nephropathy. It has been 
demonstrated that IgA in IgA nephropathy 
is abnormally glycosylated. Whereas IgA2, 
similar to IgG, contains only N-linked gly-
cans, IgA1, similar to IgD, contains both 
N- and O-linked glycans, the latter being 
present in the hinge region of the heavy 
chain. In IgA nephropathy, the O-linked 
glycans in IgA1 are smaller and contain 
less galactose and sialic acid. Th is abnor-
mality has been identifi ed by advanced 
glycobiological techniques.7,8 Differ-
ences can also be detected by straightfor-
ward binding assays with specifi c lectins, 
as has been presented by Moldoveanu et 
al.,2 who used binding of HAA lectin from 
Helix aspersa to N-acetylgalactosamine 
that becomes exposed in undergalacto-
sylated O-links on IgA1. HAA-binding 
IgA is mainly present in the polymeric 
IgA fraction of serum IgA.6
Importantly, the glycosylation abnor-
mality noticed in IgA is probably not 
related to a systemic glycosylation defect 
in IgA nephropathy patients, nor to a gen-
e ral defect in the entire B-cell lineage, as 
O-linked glycans on two other serum pro-
teins, C1 inhibitor and IgD,9 were similar 
between IgA nephropathy patients and 
controls. However, a recent study shows 
that IgA nephropathy is associated with 
polymorphisms in the regulatory region 
of the gene encoding core 1 β3-galacto-
syltransferase.10 Th is enzyme is, together 
with its chaperone Cosmc, responsible for 
galactosylation of O-linked glycans.11
Whereas circulating IgA has been exten-
sively studied, the molecular composition 
of secretory IgA has not been investigated 
in detail in IgA nephropathy patients. As 
it is clear that the subclass distribution, 
molecular composition, and glycosyla-
tion of secretory IgA are strongly diff erent 
from those of serum IgA,12 this could be 
considered as a serious gap in the current 
knowledge about IgA in IgA nephropathy. 
A link between mucosal immunity and 
IgA nephropathy is indicated by the well-
known synpharyngitic hematuria in these 
patients. Furthermore, hampered produc-
tion of antigen-specifi c mucosal IgA has 
been shown in IgA nephropathy.13
In a recent publication, the glycosyla-
tion of antigen-specifi c IgA was studied 
aft er immunization of IgA nephropathy 
patients and healthy controls, with the use 
of lectin binding assays.14 Although the 
presence of increased amounts of dega-
lactosylated IgA1 in serum of IgA neph-
ropathy patients could be confi rmed in 
this study, the authors showed that the 
glycosylation of circulating antigen-spe-
cifi c IgA, produced aft er either systemic 
or mucosal immunization, was similar 
for IgA nephropathy patients and con-
trols. Furthermore, immunization with 
a mucosal antigen induced a signifi cantly 
higher proportion of antigen-specific 
degalactosylated IgA in the circulation 
than immunization with a systemic anti-
gen, both in IgA nephropathy patients and 
in controls. Unfortunately, this study did 
not report on the composition of antigen-
specifi c IgA in secretions.
Production of degalactosylated IgA may 
be part of a physiologic immune response, 
which could be activated upon the encoun-
tering of specifi c types of antigens and/or 
confi ned to immune responses under spe-
cifi c conditions or at specifi c sites. Given 
the important differences in O-linked 
glycans between secretory IgA and serum 
IgA,12 it is apparent that the immune sys-
tem can make choices with regard to the 
nature of the O-linked glycans on pro-
duced immunoglobulins. Th ese choices 
are based on thus-far uncharacterized sig-
nals. In this context, it is conceivable that 
genetic variants involved in the regulation 
of expression of glycosylation enzymes 
predispose to IgA nephropathy.10
Taken together, this may imply that 
patients with IgA nephropathy have unu-
sual immune responses, possibly due to an 
impaired handling of mucosal antigens, 
resulting in overrepresentation of dega-
lactosylated IgA2 and fi nally mesangial 
deposition (Figure 1).
Figure 1 | Hypothetical scheme on the pathogenesis of IgA nephropathy. In the mucosal 
immune system, B cells, T cells, and dendritic cells have to deal with a continuous microbial 
exposure. In patients with IgA nephropathy, this mucosal immune response may be hampered, 
leading to persistence of infection and chronic stimulation of the mucosal immune system, 
resulting in overproduction of polymeric and partially degalactosylated IgA. This IgA can be 
secreted to the epithelial surface, but may also be directed toward the circulation. The majority 
of serum IgA is produced by the bone marrow, and bone marrow production of IgA is enhanced 
in patients with IgA nephropathy, possibly also as a consequence of immune stimulation. In 
the circulation, these processes result in increased levels of total serum IgA and of IgA with 
degalactosylated O-glycans. Degalactosylated IgA and secretory IgA have an increased interaction 
with mesangial cells, leading to deposition into the mesangium via an unidentified receptor, finally 
resulting in renal injury via cellular and humoral mechanisms.
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How does IgA cause renal disease in 
IgA nephropathy? Mesangial IgA contains 
partially degalactosylated IgA of high 
molecular weight and may also contain 
secretory IgA. Degalactosylated serum 
IgA is largely confi ned to polymeric IgA, 
and polymeric serum IgA is able to inter-
act with mesangial cells, induce mesangial 
cell activation, and trigger complement 
activation via both the lectin and the 
alternative pathways of complement. 
Some investigators showed that the pres-
ence of undergalactosylated serum IgA in 
patients is associated with histological dis-
ease parameters,15 although this could not 
be confi rmed in the study of Moldoveanu 
and colleagues.2 On the basis of numerous 
in vitro and in vivo studies, a direct role 
for IgA in induction of renal infl amma-
tion via cellular and humoral mechanisms 
is highly likely. However, at present, the 
mechanisms involved in mesangial depo-
sition of (undergalactosylated) IgA are 
still incompletely defi ned.
In the paper by Moldoveanu and col-
leagues,2 a diagnostic test is presented, 
based on the established presence of 
increased amounts of degalactosylated 
IgA in the circulation of patients with 
IgA nephropathy. Diagnosis of IgA neph-
ropathy normally requires a renal biopsy, 
in which immune fl uorescence studies 
are decisive. Th erefore, IgA nephropa-
thy patients would clearly benefi t from 
the development of an adequate but less 
invasive test. Th e specifi city of the present 
glycan-specifi c test for IgA nephropathy 
was 90%, which was similar to that of the 
assessment of total IgA concentration.2 
However, the sensitivity of the glycosyla-
tion test is remarkably better, indicating 
that the increased presence of undergalac-
tosylated IgA is much more common in 
IgA nephropathy patients than the pres-
ence of increased total serum IgA. With 
the current sensitivity of 70%, especially 
a positive test result in combination with 
appropriate clinical presentation could 
be useful and suffi  cient for diagnosis and 
treatment, whereas a negative test result 
requires further examinations.
In the setting of patients presenting with 
suspicion of renal disease, it is important 
that such a test should be evaluated with 
appropriate disease controls, including 
patients with urinary abnormalities and 
patients with renal failure. Th ese condi-
tions may aff ect the total serum IgA levels, 
and hypothetically also the glycosylation 
of IgA. In particular, the question would 
be whether this test could distinguish IgA 
nephropathy patients with isolated hema-
turia from other patients with asympto-
matic hematuria, suff ering, for example, 
from thin basement membrane disease. 
Unfortunately, such an analysis is not 
provided in the paper by Moldoveanu et 
al.2 Furthermore, currently the test has 
only been evaluated in Caucasians, and 
studies in other ethnicities are required. 
Th ese types of studies are essential for the 
evaluation of the clinical usefulness of this 
test, because they determine the specifi -
city of the test. It would be interesting to 
evaluate this serologic test together with 
other clinical and serologic parameters of 
disease. Th is approach may reveal com-
binations of test results that are highly 
specifi c for IgA nephropathy, which can 
make the diagnosis defi nitive in a subset 
of patients. Certain combinations of test 
results may further increase the sensitivity 
of this assay.
In summary, undergalactosylated IgA 
is likely to play a major role in IgA neph-
ropathy. Future studies are warranted to 
defi ne, on the one hand, the immuno-
logical mechanisms leading to overpro-
duction of this IgA, including the role of 
the mucosal immune system, and on the 
other hand, the mechanisms involved in 
renal trapping. In the meantime, this vari-
ant IgA should be further evaluated as a 
useful noninvasive diagnostic marker.
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